Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - CTI BIOPHARMA CORP | Financial_Report.xls |
| EX-32 - EX-32 - CTI BIOPHARMA CORP | ctic-ex32_201409308.htm |
| EX-31.1 - EX-31.1 - CTI BIOPHARMA CORP | ctic-ex311_201409306.htm |
| EX-31.2 - EX-31.2 - CTI BIOPHARMA CORP | ctic-ex312_201409309.htm |
| EX-10.2 - EX-10.2 - CTI BIOPHARMA CORP | ctic-ex102_20140930621.htm |
| EX-10.1 - EX-10.1 - CTI BIOPHARMA CORP | ctic-ex101_20140930817.htm |
| 10-Q - 10-Q - CTI BIOPHARMA CORP | ctic-10q_20140930.htm |
Exhibit 15
August 4, 2014
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We are aware that our report dated August 4, 2014 on our review of interim financial information of CTI BioPharma Corp. (formerly known as Cell Therapeutics, Inc.) for the three- and six-month periods ended June 30, 2014 and 2013, and included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2014, is incorporated by reference in the Registration Statements of Cell Therapeutics, Inc. on Form S-3 (File Nos. 333-177506, 333-182330, 333-183037, 333-192748, and 333-192749) and on Form S-8 (File Nos. 333-65200, 333-58957, 333-35919, 333-97015, 333-106568, 333-106571, 333-112791, 333-118016, 333-146624, 333-152168, 333-158260, 333-162955, 333-170044, 333-178158, 333-184004, 333-189611, and 333-196510).
Yours very truly,
/s/ Marcum LLP
Marcum LLP
San Francisco, California